Recommendation for antiplatelet therapy.
| Indication . | Specific features . | Recommended therapy . |
|---|---|---|
| AF indicates atrial fibrillation; PAF, paroxysmal AF; ASA, acetyl salicylic acid; OAC, oral anticoagulation; STE, ST-segment elevation; NSTE, non-STE; ACS, acute coronary syndrome; Clop, clopidogrel; PCI, percutaneous intervention; BMS, bare metal stent; DES, drug-eluting stent; TIA, transient ischemic attack; PAD, peripheral arterial disease | ||
| AF/PAF | < 75 y, w/o risk factors 1 risk factor > 2 risk factors or previous ischemic event | ASA 75–162 mg/d ASA or OAC OAC |
| Primary prevention | ASA 75–100 mg/d | |
| NSTE ACS | ASA 162–325 mg loading then ASA 75–100 mg/d Clop 300/600 mg then 75 mg/d ± GPIIb/IIIa inhibitors | |
| STE ACS | < 12 h of symptoms | PCI/thrombolysis ASA 75–100 mg/d Clop 300/600 mg then 75 mg/d ± GPIIb/IIIa inhibitors |
| PCI + stent | BMS | ASA + Clop (1 m to 1 y) |
| DES | ASA + Clop (at least 1 y) ± GPIIb/IIIa inhibitors | |
| Stroke/TIA | ASA ± dipyridamole ± Clop | |
| PAD | ASA/cilostazol | |
| Indication . | Specific features . | Recommended therapy . |
|---|---|---|
| AF indicates atrial fibrillation; PAF, paroxysmal AF; ASA, acetyl salicylic acid; OAC, oral anticoagulation; STE, ST-segment elevation; NSTE, non-STE; ACS, acute coronary syndrome; Clop, clopidogrel; PCI, percutaneous intervention; BMS, bare metal stent; DES, drug-eluting stent; TIA, transient ischemic attack; PAD, peripheral arterial disease | ||
| AF/PAF | < 75 y, w/o risk factors 1 risk factor > 2 risk factors or previous ischemic event | ASA 75–162 mg/d ASA or OAC OAC |
| Primary prevention | ASA 75–100 mg/d | |
| NSTE ACS | ASA 162–325 mg loading then ASA 75–100 mg/d Clop 300/600 mg then 75 mg/d ± GPIIb/IIIa inhibitors | |
| STE ACS | < 12 h of symptoms | PCI/thrombolysis ASA 75–100 mg/d Clop 300/600 mg then 75 mg/d ± GPIIb/IIIa inhibitors |
| PCI + stent | BMS | ASA + Clop (1 m to 1 y) |
| DES | ASA + Clop (at least 1 y) ± GPIIb/IIIa inhibitors | |
| Stroke/TIA | ASA ± dipyridamole ± Clop | |
| PAD | ASA/cilostazol | |